LT2970980T - Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose - Google Patents

Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose

Info

Publication number
LT2970980T
LT2970980T LTEP14768761.0T LT14768761T LT2970980T LT 2970980 T LT2970980 T LT 2970980T LT 14768761 T LT14768761 T LT 14768761T LT 2970980 T LT2970980 T LT 2970980T
Authority
LT
Lithuania
Prior art keywords
galactose
control
acid content
sialic acid
manufacturing methods
Prior art date
Application number
LTEP14768761.0T
Other languages
English (en)
Inventor
Marcel FLIKWEERT
Charles Goochee
Francis Maslanka
Francisus Johannes Ignatius NAGEL
James RYLAND
Eugene SCHAFER
Original Assignee
Janssen Biotech, Inc.
Janssen Biologics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51528780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2970980(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc., Janssen Biologics B.V. filed Critical Janssen Biotech, Inc.
Publication of LT2970980T publication Critical patent/LT2970980T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
LTEP14768761.0T 2013-03-15 2014-03-07 Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose LT2970980T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791094P 2013-03-15 2013-03-15
PCT/US2014/021574 WO2014149935A1 (en) 2013-03-15 2014-03-07 Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins

Publications (1)

Publication Number Publication Date
LT2970980T true LT2970980T (lt) 2018-10-25

Family

ID=51528780

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14768761.0T LT2970980T (lt) 2013-03-15 2014-03-07 Gamybos būdas kontroliuoti c galinio lizino, galaktozės ir sialo rūgšties kiekį rekombinantiniuose baltymuose

Country Status (27)

Country Link
US (3) US20140273092A1 (lt)
EP (1) EP2970980B2 (lt)
JP (1) JP2016512029A (lt)
KR (1) KR102216003B1 (lt)
CN (1) CN105378086B (lt)
AR (2) AR095660A1 (lt)
AU (2) AU2014237635B2 (lt)
BR (1) BR112015022971B1 (lt)
CA (1) CA2907140A1 (lt)
CY (1) CY1120980T1 (lt)
DK (1) DK2970980T3 (lt)
EA (1) EA201591807A1 (lt)
ES (1) ES2690047T3 (lt)
HR (1) HRP20181741T1 (lt)
IL (1) IL240689B (lt)
LT (1) LT2970980T (lt)
MX (1) MX366910B (lt)
PH (1) PH12015501837B1 (lt)
PL (1) PL2970980T3 (lt)
PT (1) PT2970980T (lt)
RS (1) RS57791B1 (lt)
SG (1) SG11201507577RA (lt)
SI (1) SI2970980T1 (lt)
SM (1) SMT201800550T1 (lt)
TW (1) TWI630216B (lt)
WO (1) WO2014149935A1 (lt)
ZA (1) ZA201507671B (lt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
JP2016512029A (ja) * 2013-03-15 2016-04-25 ヤンセン バイオテツク，インコーポレーテツド 遺伝子組換えタンパク質中のｃ末端リジン、ガラクトース、及びシアル酸含量を制御する製造方法
SG11201601262QA (en) 2013-08-20 2016-03-30 Lek Pharmaceuticals CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
SMT202200118T1 (it) 2015-11-03 2022-05-12 Janssen Biotech Inc Anticorpi che legano specificamente pd-1 e loro usi
JP2018536404A (ja) * 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
KR20180087430A (ko) 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
CN109863170B (zh) 2016-08-12 2024-08-16 詹森生物科技公司 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
CN109843916B (zh) 2016-08-12 2023-10-31 詹森生物科技公司 具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018282094B2 (en) 2017-06-05 2024-06-27 Janssen Biotech, Inc. Antibodies that specifically bind PD-1 and methods of use
CN110785185B (zh) 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
WO2019077628A1 (en) * 2017-10-16 2019-04-25 Council Of Scientific & Industrial Research ZINC SUPPLEMENTATION TO DECREASE GALACTOSYLATION OF RECOMBINANT GLYCOPROTEINS
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CA3125443A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
CN114375302B (zh) 2019-07-26 2024-12-24 詹森生物科技公司 包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
CR20220054A (es) 2019-08-15 2022-06-06 Janssen Biotech Inc Materiales y métodos para fragmentos variables de cadena única mejorado
US20240293453A1 (en) 2020-03-13 2024-09-05 Janssen Biotech, Inc. Materials and methods for binding siglec-3/cd33
IL298444A (en) 2020-05-27 2023-01-01 Janssen Biotech Inc Proteins containing cd3 antigen binding sites and uses thereof
EP4188439A2 (en) 2020-07-29 2023-06-07 Janssen Biotech, Inc. Proteins comprising hla-g antigen binding domains and their uses
AR123767A1 (es) 2020-10-13 2023-01-11 Janssen Biotech Inc Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
JP2023548034A (ja) 2020-10-22 2023-11-15 ヤンセン バイオテツク，インコーポレーテツド デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
EP4314056A1 (en) 2021-03-24 2024-02-07 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
KR20230160314A (ko) 2021-03-24 2023-11-23 얀센 바이오테크 인코포레이티드 Cd22 및 cd79b를 표적화하는 항체
US20240409634A1 (en) 2021-09-13 2024-12-12 Janssen Biotech, Inc. CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
AU2022392829A1 (en) 2021-11-22 2024-07-11 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
US20250136688A1 (en) 2023-08-07 2025-05-01 Janssen Biotech, Inc. Stabilized cd3 antigen binding agents and methods of use thereof
WO2025032508A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof
TW202535935A (zh) * 2023-12-20 2025-09-16 美商艾普吉醫療股份有限公司 結合介白素13之抗體之醫藥組合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DE3888224T2 (de) 1987-04-24 1994-07-21 Teijin Ltd Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
FR2807767B1 (fr) † 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2450289A1 (en) † 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US20040185047A1 (en) 2003-03-21 2004-09-23 Jill Giles-Komar Anti- TNF antibodies, compositions, methods and uses
KR101196103B1 (ko) † 2004-11-02 2012-11-01 아레스 트레이딩 에스.에이. 포유동물 세포용 무?혈청 세포 배양 배지
CA2720610C (en) * 2008-04-07 2016-08-23 Bayer Healthcare Llc Methods of recombinant production of glycoproteins
ES2560470T3 (es) * 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
EP2729561A4 (en) 2011-07-08 2015-06-24 Momenta Pharmaceuticals Inc CELL CULTURE METHOD
US9181572B2 (en) * 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
JP2016512029A (ja) * 2013-03-15 2016-04-25 ヤンセン バイオテツク，インコーポレーテツド 遺伝子組換えタンパク質中のｃ末端リジン、ガラクトース、及びシアル酸含量を制御する製造方法

Also Published As

Publication number Publication date
EP2970980A4 (en) 2016-09-07
PL2970980T3 (pl) 2019-01-31
PH12015501837B1 (en) 2022-02-11
IL240689B (en) 2021-12-01
CN105378086A (zh) 2016-03-02
RS57791B1 (sr) 2018-12-31
EP2970980B2 (en) 2022-07-27
AR095660A1 (es) 2015-11-04
ZA201507671B (en) 2017-11-29
AU2014237635A1 (en) 2015-09-03
CY1120980T1 (el) 2019-12-11
SMT201800550T1 (it) 2019-01-11
PH12015501837A1 (en) 2015-11-09
BR112015022971B1 (pt) 2022-05-17
EA201591807A1 (ru) 2016-02-29
ES2690047T3 (es) 2018-11-19
KR102216003B1 (ko) 2021-02-16
IL240689A0 (en) 2015-10-29
US20160237149A1 (en) 2016-08-18
JP2016512029A (ja) 2016-04-25
EP2970980A1 (en) 2016-01-20
AR124871A2 (es) 2023-05-17
AU2020203864B2 (en) 2022-05-26
BR112015022971A2 (pt) 2017-11-14
US20140273092A1 (en) 2014-09-18
US20220089712A1 (en) 2022-03-24
CN105378086B (zh) 2019-05-28
AU2020203864A1 (en) 2020-07-02
MX366910B (es) 2019-07-30
PT2970980T (pt) 2018-11-19
KR20150129025A (ko) 2015-11-18
TW201441263A (zh) 2014-11-01
WO2014149935A1 (en) 2014-09-25
MX2015012361A (es) 2016-04-28
EP2970980B1 (en) 2018-08-15
AU2014237635B2 (en) 2020-03-12
DK2970980T3 (en) 2018-10-22
SI2970980T1 (sl) 2018-11-30
TWI630216B (zh) 2018-07-21
SG11201507577RA (en) 2015-10-29
US11149085B2 (en) 2021-10-19
HRP20181741T1 (hr) 2018-12-28
CA2907140A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
ZA201507671B (en) Manufacturing methods to control c-terminal lysine, galactose and sialic acid content in recombinant proteins
WO2014151878A3 (en) Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
IL243902A0 (en) An antibody that specifically binds to glp-1r and its fusion protein with glp-1
ZA201503097B (en) Production of recombinant vaccine in e. coli by enzymatic conjugation
IL279676A (en) Recombinant proteins and therapeutic uses
IL232073A0 (en) Recombinant human naglu protein and its uses
CL2014003568A1 (es) Células transformadas para producir iduronato-2-sulfatasa (i2s) recombinante; método de producción de i2s recombinante; y proteína i2s recombinante.
SG11201505195TA (en) Methods For Reducing Aggregate Content In Protein Preparations
EP3083966A4 (en) Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
SG11201403814RA (en) Production of recombinant proteins with simple glycoforms
IN2014DN00161A (lt)
EP2971035A4 (en) RECOMBINED POLYPEPTIDE PRODUCTION
GB201304973D0 (en) Recombinant protein
EP3000890A4 (en) Alphaviral vectors and cell lines for producing recombinant proteins
GB201306114D0 (en) Improvements in and relating to the production and control of ions
SG11201600682PA (en) Expression vector for production of recombinant proteins in prokaryotic host cells
SG11201404180RA (en) Cho-gmt recombinant protein expression
IL240639A0 (en) Formulations and methods for increased recombinant production of protein
GB201308120D0 (en) Recombinant protein and method for its production
SG11201600725WA (en) Method for the recombinant production of a polypeptide in prokaryotic cells
GB201320209D0 (en) Improvements in or relating to protein Micro-nets
GB201315578D0 (en) Protein delivery to membranes
SG11201504096RA (en) Recombinant protein
GB201300529D0 (en) Recombinant polypeptide